Paragon 28 had a negative net margin of 25.31% and a negative return on equity of 37.90%. The company had revenue of $71.75 million during the quarter, compared to the consensus estimate of $70.81 ...
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of ...
The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our ...
Arizona State Retirement System decreased its position in shares of Paragon 28, Inc. (NYSE:FNA – Free Report) by 8.6% in the fourth quarter, HoldingsChannel reports. The firm owned 10,911 shares of ...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in ...
Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting ...
ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback